Small Molecules
5 January 2017
Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease4 January 2017
BioPharmX Completes Enrollment of BPX-01 Phase 2b OPAL Clinical Trial for Acne Vulgaris4 January 2017
NeuroRx announces FDA IND clearance for NRX-101 phase 2b/3 study and publication of promising biomarker data4 January 2017
Regorafenib from Bayer Granted Priority Review in the U.S. for Second-Line Treatment of Liver Cancer4 January 2017
Newron announces encouraging preliminary results of its Phase IIa study with Evenamide in patients with schizophrenia3 January 2017
Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation3 January 2017
Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia3 January 2017
Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)3 January 2017
Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma30 December 2016
Innocoll Receives Refusal to File Letter from U.S. FDA for XARACOLL® (bupivacaine HCl collagen-matrix implants) New Drug Application29 December 2016
Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV23 December 2016
NeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinson’s Disease22 December 2016
BeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-29022 December 2016
Biohaven Enrolls First Patient in Pivotal Trial of BHV-4157 in Patients With Hereditary Spinocerebellar Ataxia22 December 2016
Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis22 December 2016
FDA Accepts Supplemental New Drug Application for Pfizer’s IBRANCE® (palbociclib) in HR+, HER2- Metastatic Breast Cancer22 December 2016
PharmaMar and Chugai Pharmaceutical Enter into a License and Commercialization Agreement for PM1183 in JapanNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports